Inhibition of cholesteryl ester transfer protein (CETP): Different in vitro characteristics of RO4607381/JTT-705 and torcetrapib (TOR)

被引：16
|
作者：
Niesor, E. J. [1 ]
von der Marck, E. [1 ]
Brousse, M. [1 ]
Maugeais, C. [1 ]
机构：
[1] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
来源：
ATHEROSCLEROSIS | 2008年 / 199卷 / 01期
关键词：
D O I：
10.1016/j.atherosclerosis.2008.04.024
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [31] CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects
    Thomas, Tiffany
    Zhou, Haihong
    Karmally, Wahida
    Ramakrishnan, Rajasekhar
    Holleran, Stephen
    Liu, Yang
    Jumes, Patricia
    Wagner, John A.
    Hubbard, Brian
    Previs, Stephen F.
    Roddy, Thomas
    Johnson-Levonas, Amy O.
    Gutstein, David E.
    Marcovina, Santica M.
    Rader, Daniel J.
    Ginsberg, Henry N.
    Millar, John S.
    Reyes-Soffer, Gissette
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2017, 37 (09) : 1770 - +
  • [32] REGULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) ACTIVITY - REVIEW OF IN-VITRO AND IN-VIVO STUDIES
    LAGROST, L
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1994, 1215 (03): : 209 - 236
  • [33] The in Vitro Plasma Distribution of a Novel Cholesteryl Ester Transfer Protein Inhibitor, Torcetrapib, Is Influenced by Differences in Plasma Lipid Concentrations
    S. D. Lee
    K. M. Wasan
    A. Calcagni
    M. Avery
    F. McCush
    C. Chen
    [J]. Pharmaceutical Research, 2006, 23 : 1025 - 1030
  • [34] The in vitro plasma distribution of a novel cholesteryl ester transfer protein inhibitor, torcetrapib, is influenced by differences in plasma lipid concentrations
    Lee, S. D.
    Wasan, K. M.
    Calcagni, A.
    Avery, M.
    McCush, F.
    Chen, C.
    [J]. PHARMACEUTICAL RESEARCH, 2006, 23 (05) : 1025 - 1030
  • [35] Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition
    Hu, Xiao
    Dietz, Jessica D.
    Xia, Chunsheng
    Knight, Delvin R.
    Loging, William T.
    Smith, Andrew H.
    Yuan, Haodan
    Perry, David A.
    Keiser, Joan
    [J]. ENDOCRINOLOGY, 2009, 150 (05) : 2211 - 2219
  • [36] Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib
    Clark, RW
    Sutfin, TA
    Ruggeri, RB
    Willauer, AT
    Sugarman, ED
    Magnus-Aryitey, G
    Cosgrove, PG
    Sand, TM
    Wester, RT
    Williams, JA
    Perlman, ME
    Bamberger, MJ
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (03) : 490 - 497
  • [37] Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice
    Bell, Thomas A., III
    Graham, Mark J.
    Lee, Richard G.
    Mullick, Adam E.
    Fu, Wuxia
    Norris, Dan
    Crooke, Rosanne M.
    [J]. JOURNAL OF LIPID RESEARCH, 2013, 54 (10) : 2647 - 2657
  • [38] Torcetrapib-induced blood pressure elevation is independent of cholesteryl ester transfer protein inhibition and is accompanied by an increase in circulating aldosterone levels
    Forrest, Michael J.
    Bloomfield, Daniel
    Briscoe, Richard J.
    Ehrhart, Juliann
    Hershey, James C.
    Ma, Xiuying
    Peterson, Laurence B.
    Siegl, Peter K.
    Sinclair, Peter J.
    Stevenson, Andra S.
    Sun, Shu-Yu
    Vargas, Hugo M.
    Walker, Matthew
    Sparrow, Carl P.
    [J]. CIRCULATION RESEARCH, 2007, 101 (11) : 1209 - 1209
  • [39] Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case
    Barter, Philip J.
    Nicholls, Stephen J.
    Kastelein, John J. P.
    Rye, Kerry-Anne
    [J]. CIRCULATION, 2015, 132 (05) : 423 - 431
  • [40] Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?
    Hovingh, G. Kees
    Ray, Kausik K.
    Boekholdt, S. Matthijs
    [J]. CIRCULATION, 2015, 132 (05) : 433 - 439
12345